Please assess the completion status of the following clinical trial:

Trial Title: HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Tumor cell phenotype consistent with B-CLL~2. Patients with active B-CLL and with an indication for treatment~3. Failing at least one fludarabine-containing treatment regimen~4. Failing at least one alemtuzumab-containing treatment regimen~5. ECOG Performance Status of 0, 1, or 2~6. Life expectancy of at least 4 months~Exclusion Criteria:~1. Previous treatment with alemtuzumab within 6 weeks prior to Visit 2~2. Previous autologous stem cell transplantation within 6 months prior to Visit 2~3. Allogeneic stem cell transplantation~4. Radioimmunotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ofatumumab (Type: EXPERIMENTAL): Anti-CD20 antibody therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).